Iloperidone

Iloperidone

SCHEMBL115755

COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2HTR2A

The experimentally established mechanism targets of Iloperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 1/20 1.00
HTR2A known ✓ P28223 1/20 1.00
ABCB11 O95342 1/20 1.00
CHRM2 P08172 1/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00
CHRM1 P11229 1/20 1.00
ADRA2B P18089 1/20 1.00
ADRA2C P18825 1/20 1.00
DRD1 P21728 1/20 1.00
DRD4 P21917 1/20 1.00
ACHE P22303 1/20 1.00
SLC6A2 P23975 1/20 1.00
HTR2C P28335 1/20 1.00
SLC6A4 P31645 1/20 1.00
CCKBR P32239 1/20 1.00
ADRA1A P35348 1/20 1.00
HRH1 P35367 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iloperidone SCHEMBL29374709 1.00 ABCB11 (1.00) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL28132950 0.99 ABCB11 (0.98) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL1804111 0.99 ABCB11 (0.98) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL1805470 0.99 ABCB11 (0.98) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL28003560 0.99 ABCB11 (0.98) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL1802619 0.99 ABCB11 (0.98) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL4534147 0.98 ABCB11 (0.97) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL1803151 0.98 ABCB11 (0.97) ABCB11CHRM2HTR1AADRA2ACHRM1
Iloperidone SCHEMBL1801974 0.98 ABCB11 (0.95) ABCB11CHRM2HTR1AADRA2ACHRM1
SCHEMBL1545106 0.98 ABCB11 (0.95) ABCB11CHRM2HTR1AADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9182 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094963-A Cardioprotective lipids and methods of use 2026-05-26 CN claimed
US-12617809-B2 Cardioprotective lipid and method of use SIGNPATH PHARMA, INC. (US) 2026-05-05 US claimed
US-12606869-B2 Methods for the administration of iloperidone Vanda Pharmaceutials Inc. (US) 2026-04-21 US claimed
EP-4725483-A1 COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE Université de Bordeaux (FR) 2026-04-15 EP claimed
US-20260083759-A1 Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders HADASIT MED RES SERVICE (IL) 2026-03-26 US claimed
US-20260048062-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF PSYCHOSIS AND PSYCHOTIC DISORDERS OVID THERAPEUTICS INC (US) 2026-02-19 US claimed
US-12544367-B2 Method of treatment of schizophrenia VANDA PHARMACEUTICALS INC. (US) 2026-02-10 US claimed
US-12544338-B2 Solid or semisolid lipid based dosage form stabilization through curing and addition of low HLB surfactant(s) R.P. SCHERER TECHNOLOGIES, LLC (US) 2026-02-10 US claimed
EP-3507371-B1 COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM UNIV RUTGERS (US) 2026-01-28 EP claimed
US-12527754-B2 Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions TUFTS MEDICAL CENTER, INC. (US) 2026-01-20 US claimed
WO-2000023057-A2 ATYPICAL ANTIPHSYCHOTIC IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITOR FOR IMPROVING COGNITION JANSSEN PHARMACEUTICA N.V. (BE) 2000-04-27 WO claimed
US-5955459-A Fatty acid-antipsychotic compositions and uses thereof NEUROMEDICA, INC. (US) 1999-09-21 US claimed
WO-1999026661-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA PROTARGA INC. (US) 1999-06-03 WO claimed
WO-1999021422-A1 TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS CORTEX PHARMACEUTICALS, INC. (US) 1999-05-06 WO claimed
EP-0402644-B1 N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments HOECHST ROUSSEL PHARMA (US) 1995-08-16 EP claimed
US-5364866-A Side effect reduction HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1994-11-15 US claimed
EP-0612318-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1994-08-31 EP claimed
EP-0542136-A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-05-19 EP claimed
WO-1993009102-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1993-05-13 WO claimed
EP-0402644-A1 N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1990-12-19 EP claimed